Leerink Partnrs Weighs in on Vincerx Pharma FY2024 Earnings

Vincerx Pharma, Inc. (NASDAQ:VINC) – Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for shares of Vincerx Pharma in a report issued on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of ($0.50) per share for the year, down from their previous estimate of ($0.38). The consensus estimate for Vincerx Pharma’s current full-year earnings is ($0.38) per share. Leerink Partnrs also issued estimates for Vincerx Pharma’s Q4 2024 earnings at ($0.13) EPS and FY2025 earnings at ($0.32) EPS.

Separately, Leerink Partners lowered their target price on Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Vincerx Pharma Price Performance

Shares of Vincerx Pharma stock opened at $0.30 on Friday. The stock has a market cap of $9.90 million, a P/E ratio of -0.29 and a beta of 1.60. The stock’s 50 day simple moving average is $0.51 and its 200-day simple moving average is $0.63. Vincerx Pharma has a 1-year low of $0.29 and a 1-year high of $9.37.

Vincerx Pharma (NASDAQ:VINC) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Vincerx Pharma by 29.9% in the first quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock valued at $3,375,000 after acquiring an additional 153,575 shares during the last quarter. Marshall Wace LLP lifted its holdings in Vincerx Pharma by 359.1% in the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock valued at $266,000 after acquiring an additional 256,967 shares during the last quarter. Finally, Armistice Capital LLC acquired a new position in Vincerx Pharma in the second quarter valued at approximately $1,610,000. 44.02% of the stock is currently owned by institutional investors and hedge funds.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.